Pharos iBio Co., Ltd. (KOSDAQ: A388870)
Health Care · Biotechnology · KR
₩5,670.00
+2.90% today · -5.7% 1Y
Pharos iBio Co., Ltd. (KOSDAQ: A388870) operates in the Biotechnology industry within the Health Care sector. The company is valued at $51.93M.
Over the last twelve months the share price has lost 5.7%, trading between 3.71K and 12.12K.
Tweenvest scores Pharos iBio Co., Ltd. across four factors: quality 27/100. Its strongest factor is quality.
A388870 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $51.93M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -732.86
- Dividend yield
- —
- Beta (5Y)
- -0.35
- 52-week high
- ₩12,120.00
- 52-week low
- ₩3,710.00
- Avg volume (3M)
- —
- Shares outstanding
- 12.95M
- Employees
- —
- Next earnings
- —
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $260.63 | -1.94% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $438.87 | -0.76% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.49 | -0.19% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $550.54 | -0.42% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $819.48 | -1.69% |
| argenx SEENXTBR: ARGX | $64.17B | €900.00 | +2.37% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $147.14 | -7.36% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.